Factors determining the clinical utility of serial measurements of antineutrophil cytoplasmic antibodies targeting proteinase 3

Files

Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3.pdf (685.08 KB)

Date

2017

Type:

Collections

Artículos Medicina y Ciencias de la Salud

Descargas totales

77

Vistas totales

0
Gestores bibliográficos

Authors

item.contributor.advisor

ORCID:

Journal Title

Journal ISSN

Volume Title

Publisher

Wiley

item.page.isbn

item.page.issn

item.page.issne

item.page.doiurl

URI

http://hdl.handle.net/11447/1678
 http://dx.doi.org/10.1002/art.39637

item.page.extent

11

item.page.accessRights

item.page.other

item.page.references

Abstract

OBJECTIVE: Relapse following remission is common in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), particularly with ANCAs directed at proteinase 3 (PR3). This study was unde...

Description

item.page.coverage.spatial

item.page.sponsorship

Citation

Fussner LA, Hummel AM, Schroeder DR, Silva F, Cartin-Ceba R, Snyder MR, Hoffman GS, Kallenberg CG, Langford CA, Merkel PA, Monach PA, Seo P, Spiera RF, William St Clair E, Tchao NK, Stone JH, Specks U; Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group. Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3. Arthritis Rheumatol. 2016 Jul;68(7):1700-10.

Keywords

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis , Antibodies, Antineutrophil Cytoplasmic , Myeloblastin

item.page.dc.rights

item.page.dc.rights.url

Estadísticas de uso
1 0,8 0,5 0,3 0
Septiembre 2025Octubre 2025Noviembre 2025Diciembre 2025Enero 2026Febrero 2026Marzo 2026

Implementado por OpenGeek Services